NHPN-1010 (AUDITUS)
Tinnitus, Acute SNHL (e.g., Noise-Induced), Meniere's Disease, Cochlear Implant-related HL
Phase 2 ReadyActive
Key Facts
Indication
Tinnitus, Acute SNHL (e.g., Noise-Induced), Meniere's Disease, Cochlear Implant-related HL
Phase
Phase 2 Ready
Status
Active
Company
About Otologic Pharmaceutics
Otologic Pharmaceutics is a pioneering biotech firm targeting the vast, underserved market of sensorineural hearing loss. The company has two core platforms: a Phase II-ready, oral small molecule combination therapy (NHPN-1010) for conditions like tinnitus and acute hearing loss, and a preclinical siRNA-based regenerative program (Autigen siHES1) aimed at regrowing sensory hair cells. While still pre-revenue, the company has secured non-dilutive funding from the Department of Defense and is actively seeking partnerships to advance its pipeline.
View full company profile